Preclinical studies using broad-spectrum HDAC inhibitors, such as trichostatin A and valproic acid, have demonstrated suppression of atrial fibrosis, attenuation of myofibroblast differentiation, and reduced AF inducibility in rodent and porcine models [179,180]. This evidence concerns the gene HDAC9 and atrial fibrillation.